Date:5/14/2009

arch 31, 2009 (unaudited), and December 31, 2008 March 31, 2009 December 31, ASSETS (Unaudited) 2008 -------------- ------------ Current assets Cash and cash equivalents $7,778,180 $9,404,843 Short-term investments 2,029,352 1,894,434 Trade accounts receivable 189,617 281,342 Other receivables 13,681 37,223 Prepaid expenses and other assets 177,352 282,971 ------- ------- Total current assets 10,188,182 11,900,813 Property and equipment, net 288,975 310,365 Patents, net of accumulated amortization of $40,105 and $38,588 12,915 14,433 Deposit 35,625 35,625 ------ ------ Total assets $10,525,697 $12,261,236 ----------- ----------- LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued expenses $1,180,489 $710,881 Accrued salaries and benefits 152,289 304,756 Deferred revenue 76,423 39,347 ------ ------ Total current liabilities 1,409,201 1,054,984 Deferred compensation 635,000 660,000 Deferred rent 130,124 136,736 ------- ------- Total liabilities
'/>"/>

SOURCE Spherix Incorporated Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. Spherix D-tagatose to be Supplied by Inalco SpA
4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
5. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
6. Spherix Elects New Independent Director, and Elects Chairman of the Board
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs